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Abstract

INTRODUCTION/OBJECTIVES: Current screening guidelines for pre-diabetes and
type 2 diabetes mellitus note that there are discrepancies in diagnosing the disease using
the fasting plasma glucose test, oral glucose tolerance test, and HbA1c in high-risk
populations. The objective of this study is to compare the effectiveness of screening
methods for type 2 diabetes mellitus (T2DM) and pre-diabetes by race/ethnicity and
gender.
METHODS: Secondary analyses of the National Health and Nutrition Examination
Survey (NHANES, 2005-2008) were performed using SPSS 19.0. Screening outcomes
were assessed and compared for a sample of n=10,566, NHW, NHB, MA, and
Multiracial/other men and women. Analyses included cross tabulations, ANOVA and
partial correlations to establish disease prevalence, effectiveness of screenings, and
statistical significance.
RESULTS: It was found that the HbA1c test is comparable in precision, and is
correlated with the FPG for racial and ethnic minorities. The specificities for detecting
pre-diabetes using the HbA1c were higher (64-66%) for these groups than by using the
standard, FPG screening method (42-49%). There were no strong, significant differences
for screening effectiveness for men versus women.
DISCUSSION: This study revealed that the HbA1c test might be an effective method for
screening for pre-diabetes in racial and ethnic minorities instead of the FPG test alone.
Screening in high-risk populations will help delay the onset of T2DM, with increased
prevention during the pre-clinical phase.

INDEX WORDS: Type II Diabetes Mellitus, Race, Ethnicity, Gender, Fasting Plasma
Glucose (FPG), Oral Glucose Tolerance Test (OGTT), HbA1c.
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I. INTRODUCTION

1.1-Background: Diabetes as a Public Health Problem
Diabetes is a metabolic illness that affects 246 million people worldwide, and it is the
underlying cause of morbidity and mortality for many other chronic illnesses (World Health
Organization, 2011). Globally and especially, in the United States, Type 2 diabetes mellitus
(T2DM) accounts for 90% of documented cases. An analysis of healthcare expenditures related
to the cost of T2DM projects that, in the U.S., $4.3 trillion will be spent on diabetes treatment by
2017 (Ariza, 2010). In the United States (U.S.), expenditures related to T2DM are $174 billion
annually (Ariza, 2010). These costs include the management of complications of the disease,
such as blindness, neuropathy, cardiovascular disease, kidney failure, and limb amputations.
Diabetes occurs when a person has blood glucose levels above 100 milligrams per
deciliter (mg/dL) on a chronic basis (APHA, 2010 and National Diabetes Information
Clearinghouse, 2008). Diabetes mellitus results from two types of endocrine malfunction that
increase blood glucose levels: 1) pancreatic beta cells lose the ability to secrete the insulin that
enables the body to metabolize glucose (Type 1), or 2) although insulin is secreted, the body‟s
cells become resistant to its effects and glucose is not metabolized (Type 2).
The prevalence of type I diabetes mellitus (T1DM) is about 215,000 children and young
adults (less than 18 years of age). T1DM is an autoimmune response in which the body destroys
the insulin-secreting, β-cells in the pancreas (Bluestone, 2010). Without insulin, the body cannot
metabolize glucose, blood glucose levels rise, and energy is not available to the body. In the
absence of cellular glucose, fatty tissue becomes the alternate source of energy. This process is
called diabetic ketoacidosis, and the byproducts (ketones) are poisonous (Eisenbarth GS, 2008).
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Insulin therapy has helped to improve the quality of life for those who actively monitor their
glycemic levels, which is the measure of glucose in the blood. (American Diabetes Association,
2010).
In the U.S. T2DM affects around 25.8 million people, and is believed to be undiagnosed
in around 7 million of the 25.8 million cases. Researchers identified undiagnosed cases using
surveys from the Indian Health Services, CDC, NIH, and U.S. Census Bureau, and other large
databases (National Center for Chronic Disease and Health Promotion, 2011). Patients that are
undiagnosed have not been previously identified as a diabetic or pre-diabetic, yet tests positively
for either category (National Center for Chronic Disease and Health Promotion, 2011). Figure 1
displays the national distribution of T2DM in the U.S. for the year 2008. Those with T2DM
have the problem of too much insulin or glucose in the blood stream, called hyperglycemia. In
this scenario, the pancreas cannot keep up with the demand of insulin metabolism, and this leads
to insulin resistance (National Center for Chronic Disease Prevention and Health Promotion,
2011).
T2DM is the seventh-leading cause of death, causes kidney failure, and is the top reason
for non-traumatic amputations (National Center for Chronic Disease Prevention and Health
Promotion, 2011). High, chronic levels of blood glucose and insulin lead to damage of organs,
tissues and nerves. Some chronic conditions associated with T2DM are, hypertension, blindness,
neuropathy (nerve damage), kidney disease, and an increased risk of heart disease and stroke
(American Diabetes Association, 2011).
This condition is mostly observed in adults, (more than 18 years of age), who tend to
have more fatty tissue than children do. However, the rise of obesity, poor nutrition, and
sedentary behaviors is increasing the number of children diagnosed with T2DM. It is also
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important to note that the prevalence of children with diabetes (215,000) includes cases of
T1DM and T2DM.
Type 2 diabetes mellitus involves a complex interaction between genetics and the
environment, and there are proximal factors (family and friends) and distal factors (society and
norms) that can influence health behaviors (Centers for Disease Control and Prevention, 2009).
In T2DM, these interactions often involve genetics, poor diet/nutrition due to the economy, lack
of physical activity because of unsafe neighborhoods, or any other combination of prolonged life
events.
Figure 1: 2008 Age-Adjusted Estimates of the Percentage of Adults with Diagnosed
Diabetes

Image adapted from Centers for Disease Control and Prevention: National Diabetes
Surveillance System. Available online
at: http://apps.nccd.cdc.gov/DDTSTRS/default.aspx. Retrieved 10/4/2011

1.2 - Pre-Diabetes
Pre-diabetes, defined as blood glucose levels above normal but below 126 mg/dL for the
fasting plasma blood glucose test (FPG). Pre-diabetes occurs when glycemic levels fall below
199 mg/dL for the oral glucose tolerance test (OGTT) but above normal. Pre-diabetes is the
inability to metabolize insulin, and termed “Impaired Fasting Glucose" (IFG) or Impaired
Glucose Tolerance (IGT). The categorization of the two depends on the type of glucose test
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administered (National Diabetes Clearinghouse, 2008) (see discussion blow). The results of the
Diabetes Prevention Program, a large randomized control trial (Diabetes Prevention Program
Research Group, 2009), led the ADA, and other medical professionals to advise that prediabetics receive greater attention for lifestyle and/or pharmaceutical interventions (American
Diabetes Association, 2010).
1.3- Burden of Insulin Resistance for Racial and Ethnic Minorities and Women
Insulin resistance plays a huge role in the disparities seen for the distributions of T2DM
for African Americans and Hispanics compared to non-Hispanic Whites (Carnethon, 2002 and
Hasson, 2010). Several studies associate chronic hyperglycemia with the high prevalence of
T2DM (Ariza, 2010; Marshall, 2007; Dagogo-Jack, 2003). This is due to differences in waist
circumference seen in women, which contributes to visceral fat, and is associated with glucose
intolerance (Ariza, 2010). Women are also predisposed to insulin resisitance and T2DM,
because of GDM and polycistic ovary syndrome (Healthwise, 2009).
There are other risk factors for insulin resistance. Overtime, a sedentary lifestyle can
result in excess weight. Additionally, if this weight is concentrated in the midsection of the body,
the risk of hypertension is increased and likely to result in insulin resistance. Those that have
insulin resistance are likely to develop T2DM if there are no lifestyle changes or medical
interventions (National Diabetes Information Clearinghouse, 2008).
1.4-Methods of Detection

The standard methods for screening for T2DM include the oral glucose tolerance test
(OGTT), fasting plasma glucose test (FPG), and the hemoglobin A1c (HbA1c) test. The
American Academy of Family Physicians, American Diabetes Association, and American
4

College of Obstetrics and Gynecology updated their criteria for screening for T2DM in 2008,
based on the recommendations from the United States Preventive Services Task Force (USPSTF)
(Norris, 2008). The guidelines recommend (grade B) targeted blood glucose screenings for those
with blood pressure ≥ 135/90 mmHg (millimeters of mercury). This will help prevent and slow
the progression of cardiovascular complications that accompany hyperglycemia (Marshall, 2007).
The consensus is that there is still insufficient evidence regarding the use of targeted screenings
for other high-risk populations (recommendation I). There are benefits and disadvantages for
each screening method (see discussion below), but here is the standard information regarding the
available methods.
The American Diabetes Association (ADA) currently recommends initial screening for
T2DM with the fasting plasma glucose (American Diabetes Association, 2010; Norris, 2008)
though sensitivity of around 60% is much lower than oral glucose tolerance test (80%). OGTT is
the gold standard, yet is typically used in practice for pregnant women to test for gestational
diabetes mellitus (Healthwise, 2009). Both test possess room for error, and the HbA1c method is
under continuous evaluation for effectiveness in identifing high-risk populations. This test is
currently used in Japan as the initial screening for pre-diabetes, but is not an accepted method
worldwide (American Association of Clinical Endocrinologists Board of Directors and American
College of Endocrinologists Board of Trustees, 2010). The American College of Endocrinology
agrees with the ADA and recommends using the traditional methods versus the HbA1c because
the test is “misleading” in racial and ethnic minority populations, which, again, are high-risk for
T2DM and insulin resistance (American Association of Clinical Endocrinologists Board of
Directors and American College of Endocrinologists Board of Trustees, 2010).
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There are many factors influencing the differential rates of T2DM incidence and
prevalence, and the literature suggests the need to intervene in high-risk groups. However, the
USPSTF notes that there is not enough evidence for targeted screening (U.S. Preventive Services
Task Force, 2008). Futher analysis of the status of health regarding T2DM, pre-diabetes and risk
factors associated with acquiring the disease can direct points of intervention for future studies.
1.5- Purpose of Study
The purpose of this study is to examine the rate of detection or screening effectiveness of
T2DM and pre-diabetes in high-risk populations using the Fasting Plasma Glucose test (FPG),
Oral Glucose Tolerance Test (OGTT), and hemoglobin A1c (HbA1c). While FPG and OGTT
are both valid for detecting high glucose concentrations in the blood stream, the HbA1c test may
be more effective for identifying high-risk individuals, such as pre-diabetics. This group can
benefit from early detection, and even reverse the onset of illness (Diabetes Prevention Program
Research Group, 2009). Exploring screening methods, and comparing their effectiveness over
populations using demographics such as race and ethnicity, and gender or sex, will aid in
preventing more cases of T2DM in the pre-clinical stage.
1.6-Research Questions
Several studies document that the FPG and OGTT screening methods for T2DM may not
be sufficient for properly detecting those who belong to high-risk populations (Colagiuri, 2011,
Herman W. H., 2007, and World Health Organization, 2011). Another study shows that event
though FPG and OGTT are accepted screening methods, that subtle changes in behavior will
alter the results, which leads to misdiagnosing patients (Bisht, 2011). The HbA1c method is
currently used as a tool to moniter the quality of diabetic care a patient recieves, but may be an
important tool for more precise screening (Nakagami, 2007). This method currently is not
6

accepted worlwide because it is more expensive, and runs the risk of misdiagnosing high-risk
patients as well (World Health Organization, 2011). This study will use the National Health and
Nutrition Examination Survey, 2005-2008, to determine which diabetes screening methods are
most effective for racial and ethnic minorites, males and females by comparing several factors.
The following questions are considered:
Question #1-- Is there an agreement between the fasting plasma glucose test and
HbA1c against the oral glucose tolerance test for detecting type 2 diabetes mellitus
based on race/ethnicity and gender?
Question #2- Is there an agreement between the fasting plasma glucose test and
HbA1c against the oral glucose tolerance test for detecting pre-diabetes mellitus
based on race/ethnicity and gender?
Question #3-Are the screening methods effective in detecting pre-diabetes and type 2
diabetes mellitus for all race/ethnicities?
Question #4- Are the screening methods effective in detecting pre-diabetes and type
2 diabetes mellitus for both males and females?
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II. REVIEW OF THE LITERATURE
The risk of pre-diabetes and T2DM according to race/ethnicity and gender, and the
measurement of that risk, are the research questions in this study. This literature review
examines the association of race/ethnicity and gender with diabetes, and briefly introduces
common risk factors for T2DM. Descriptions of the accepted screening methods will include
descriptions of the process of administering the test, the threshold values for pre-diabetes and
T2DM, and benefits and disadvantages of each method.
2.1- Race/Ethnicity
Traditionally, social groups are clustered by racial categories, such as Non-Hispanic
Black, Non-Hispanic White, Hispanic/Latino Americans, American Indian, Asian Americans,
and Pacific Islander Americans. However, the American Anthropological Association (AAA)
has stated that race has no biological plausibility due to physical differences alone (American
Anthropological Association, 1998). Ethnicity may be a more realistic construct than race, since
those from similar regions possess certain traits that allow them to better adapt and survive in
their physical environments (American Anthropological Association, 1998). The term
race/ethnicity is now more widely used in the U.S.
Diabetes rates by race/ethnicity

Differences in the rates of obesity are likely a major contributor to the variations in
T2DM seen in different racial and ethnic groups. For example, Felicia Hodge and others looked
at the health status of morbidly obese women who were American Indians, and found that 34%
of the population was obese, a percentage 1.6 times as high as whites (2011). Black women
were the only other groups with similar rates of obesity, ranging from 30-37% (Hodge, 2011).
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There are several theories regarding these findings. Though hyperglycemia was thought
to be the result of increased BMI, one study controlled for BMI and still found that non-obese
African American women had a higher glycemic index compared to non-obese white women
(Dagogo-Jack, 2003). The thrifty gene theory offers one explanation. Ethnic minorities
originating from "hunter-gatherer" nations are thought to possess a "thrifty gene.” In times of
feast, the body adapted by storing excess insulin/glucose from consumed food for use during
times of famine (National Center for Chronic Disease Prevention and Health Promotion, 2011).
In modern society where food is plentiful, this characteristic may lead to obesity, which increases
the risk of T2DM (Dagogo-Jack, 2003). Minority groups are more likely to report the perception
that their health care providers discriminated against them. Those same patients are more likely
to report poor health status as opposed to majority social groups (Coreil, 2010).
The National Institutes of Health funded a study as a supplement to the larger study
called the Physicians‟ Understanding of Human Genetic Variation (PUHGV) Study at the Social
and Behavioral Research Branch of the National Human Genome Research Institute (Snipes,
2011). The goal was to see how physicians understood the role of genetics and race/ethnicity for
the diagnosis and prognosis of T2DM. The study recruited 50 physicians in metro areas around
the U.S., and qualitatively assessed whether or not race influenced the way they treated their
minority patients. All physicians agreed that patient and family histories are most important to
guide treatment and recommendations. Many also believed race/ethnicity to be a risk factor for
some conditions (Snipes, 2011). Additional discussions of risk factors associated with
race/ethnicity are provided below.
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2.2- Diabetes Rates by Gender
Men and women have physiological differences that may put one group over the other for
risk of certain health outcomes. It is noted that as of 2010, 13.0 million men have T2DM (11.8%),
12.6 million women (10.8%) do as well. The adiposity or fat distribution is different for men
than for women (Dagogo-Jack, 2003). Women that are overweight or obese tend to gain weight
centrally, compared to men that gain the weight peripherally (Teixeira-Lemos, 2011).
Interestingly, excess adiposity affects men differently than for women. Increasing weight is a
risk factor for T2DM, yet is more adverse in women (Paek, 2010). This is due to adiposity
around the waist, and circumference of the waist and BMI is a stronger predictor of risk for
T2DM in women than in men (Paek, 2010).
Women also have different health-seeking behaviors. Women are more likely to seek the
advice of a physician, yet it is less likely they will implement recommended lifestyle
improvements (Gavin, 2011). In addition, women who have had children may be more at risk for
T2DM if during pregnancy, they had gestational diabetes mellitus (GDM) (American Diabetes
Association, 2010). Additional discussions of risk factors associated with gender are provided
below.
2.3-Other Risk Factors
Type 2 diabetes mellitus (T2DM) is the result of both genetics and lifestyle behaviors.
For example, a diet consisting of mostly high fat, low fiber foods is a risk factor for not only
T2DM, but also pre-diabetes and cardiovascular disease. Physical inactivity, low levels of highdensity lipoproteins (HDL), family history of diabetes, and hypertension are additional risk
factors that health care providers assess while screening for diabetes (American Diabetes
Association, 2010). The resolution of T2DM is shown to revert to healthier body and blood
10

measures through behavior modification (Haas, 2010). By targeting a combination of the risk
factors above and more, health professionals have prevented the on-set of T2DM (Diabetes
Prevention Program Research Group, 2009). The following is an overview of risk factors that are
strong indicators for the disease:

Family History
The association of family history to the risk of T2DM is strong. The ADA reports that the
diagnosis of a parent before the age of 50 results in a 14% increase in risk that their child
develops T2DM (American Diabetes Association, 2011). Other studies have looked for
genes that may contribute to the development of T2DM. Recent work is being done to
identify more mutations, and 18 have been found to affect fasting blood glucose and
insulin levels in healthy adults. Further studies surrounding the gene variations will help
to understand how fasting blood glucose functions, and help diabetics monitor their blood
glucose with precision (Dupuis J, 2010).
Research shows that the mutations are subtle and hard to identify, and only two specific
sequences have been named. These genes are calpain 10 (CAPN10) and hepatocyte
nuclear factor 4 alpha (HNF4A), and belong to the class of single nucleotide
polymorphisms or SNPs (McEntyre, 2004). McEntyre and others believe that the
development of T2DM does not occur without an environmental trigger (2004).
Age
The 65+ years old population is anticipated to double by 2050, which will account for
20% of the U.S. population versus the current 12% (Altpeter, 2010; Centers for Disease
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Control and Prevention and The Merck Company Foundation., 2007). Eighty percent of
the elderly will have at least one chronic health condition and 50% will have at least two
(Centers for Disease Control and Prevention and The Merck Company Foundation.,
2007; National Center for Chronic Disease Prevention and Health Promotion, 2010).
Development of T2DM has a long latency period of about 10-12 years, and in 2010,
about 26.9% of U.S. residents over the age of 65 years had diabetes (National Center for
Chronic Disease and Health Promotion, 2011). This percentage is equivalent to 10.9
million of 25.8 million people with the disease (American Diabetes Association, 2011).
The disparity of T2DM complications in older populations is credited to lower glycemic
control in African American and Hispanics patients (Weinstock, 2011). Education and
income are lower for these two groups than for whites, and these create barriers to
awareness of self-care strategies for monitoring glycemic levels.
Socioeconomic Status
Socioeconomic status is a demonstrable risk factor for many chronic health conditions,
including T2DM. Education and income directly and indirectly determine the community
where a person will live, and affect access to schools, parks, grocery stores, liquor stores,
fast food restaurants, and crack houses (Inagami, 2006). Higher education levels are
associated with better health outcomes; because this population has typically has a better
income, better access to resources that promote health and a better awareness of healthrelated options (Coreil, 2010).
The Whitehall Studies in the United Kingdom present some of the strongest research on
the effects of socioeconomic status on health. These studies followed the health and
12

social status of a large cohort of British civil servants over time. Workers in the lowest
levels of industry experienced a higher burden of morbidity, and tended to die younger,
than those in upper management did. These outcomes are similar for other studies (Coreil,
2010).
End-stage complications of T2DM, such as renal disease, eye disease, and coronary heart
disease, are often more severe for African Americans and Hispanic/Latino populations
(Ariza, 2010). At least in part, this is due to lack of access to health care, low utilization
of care, and lack of patient self-care (Gavin, 2011). Managing chronic illness can be a
challenge from month to month with low-adherence to medications. This is more likely
when there is not enough income to cover the expense of multiple medications.
Physical Inactivity
Regular physical activity helps regulate glucose levels, blood pressure and help with
weight control, yet most people are physically inactive (Figure 2). Physical activity is
loosely defined as being active for at least 30 minuntes on most days (National Center for
Chronic Disease Prevention and Health Promotion, 2011, Teixeira-Lemos, 2011).
Barriers to physical activity may be the lack of a safe space for recreation in one‟s
neighborhood, or a pre-existing condition that makes it hard to be physically active.
Though people trust their doctor's advice, research shows that although patients are
advised to increase physical activity, they often do not (Gavin, 2011).
Physical inactivity is most prevalent for women, especially racial and ethnic minorities.
The disparity for physical inactivity in African American and Hispanics women is
initially seen in adolescence. Early on-set of puberty is a possible barrier to physical
13

activity, and this health behavior carries into adulthood (Belsky, 2010). It is also noted
that men are more likely to engage in physical activity than women (27% versus 25%)
are. Also NHB and Latino women were equally more likely to be physically inactive
(21%) (Ross C. Brownson, 2005).
A recent study analyzed health behaviors of diabetics in the 2007 the Study to Help
Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD).
The study included whites, blacks and Latinos. Many believed exercise was good for
their health, but did not get the recommended time of 30 mins of physical activity on
most days. It is also important to note that most people with T2DM are overweight or
obese, which may be a barrier to being physically active (Gavin, 2011).
Figure 2: 2008 Age-Adjusted Estimates of the Percentage of Adults Who Are Physically
Inactive

Image adapted from Centers for Disease Control and Prevention: National Diabetes
Surveillance System. Available online
at: http://apps.nccd.cdc.gov/DDTSTRS/default.aspx. Retrieved 10/4/2011
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Obesity
Body Mass Index,( BMI= (Weight in Kg/Height in m x height in m)), is a measurement
that takes into account a person‟s height, weight along with lifestyle factors that help to
determine the risk for obesity, and the diseases associated with a high value. The units of
measurement are kilograms/meter squared (kg/m2) and values greater than 25 kg/m2 are
overweight. People with a BMI over 30 kg/m2 are obese. Obesity has become a pandemic,
and is attributed to easy access to high caloric, low-nutritional foods, a sedentary lifestyle
or being physically inactive most days, low socioeconomics, (Hodge, 2011), and the
genetics of race or ethnicity. Also tied to obesity is the fact that the distribution in the
waist can indicate a higher risk for T2DM, pre-diabetes, and CVD. Increased adiposity
in the waist increases blood pressure and stress on the heart, which can increase damage
because of excess blood glucose. In addition to BMI, waist circumference can better
predict the risk since BMI can be misleading for those that are athletic.
Huffman and others found an association between waist circumference, BMI, and CReactive proteins in Cuban Americans, who are at a higher-risk for T2DM that nonHispanic Caucasians. The association of C-Reactive Proteins (CRP) levels is the protein
markers for low-levels of chronic inflammation. The accumulation of adipose or fatty
tissue increases CRP levels. Huffman notes that CRP may be a risk factor for developing
DM, and speed the progression of CVD (Huffman, 2010). Increasing physical activity
and sustaining an active lifestyle can serve as an anti-inflammatory agent, and prevent
T2DM (Teixeira-Lemos, 2011). Figure 3 represents obesity in adults ages 20 and older
for 2008.
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Figure 3: 2008 Age-Adjusted Estimates of the Percentage of Adults Who Are Obese

Image adapted from Centers for Disease Control and Prevention: National Diabetes
Surveillance System: Available online
at: http://apps.nccd.cdc.gov/DDTSTRS/default.aspx. Retrieved 10/4/2011.

2.4-Screening Methods for pre-diabetes and T2DM in High-Risk Patients

Oral Glucose Tolerance Test (OGTT)
The “gold standard” for screening for T2DM is the OGTT, because the test is able to
capture around 80% of those who are screened that truly have the disease. The test
requires an eight-hour fast, and then return to the office to drink 75 g of a glucose-rich
liquid. There is a two-hour resting period, and then blood is drawn for analysis. The
threshold for diabetes is a glucose level over 199 mg/dL. Patients with values of 140-199
mg/dL are considered to have Impaired Glucose Tolerance (IGT). Anything below 140
mg/dL is considered normal (American Diabetes Association, 2010).
The test is effective at detecting pre-diabetes and T2DM (American Diabetes Association,
2010). However, some criticisms for the OGTT include the standards for measuring
glycemic indices. The glucose drink challenge does not mimic physiologic response to
glucose metabolism (Borai, 2011). There is intra-individual variability affected by
modifications in diet, exercise, and pre- and post-analysis. For example, anxiety before
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the test, illness, consumption of caffeine or alcohol, and changes in exercise and smoking
behaviors alters test results (Bisht, 2011). Another issue with OGTT is the reproducibility,
or ability to obtain the same reading consistently, is poor (46.6%) for IGT (Agency for
Healthcare Research and Quality, 2005).
Fasting Plasma Glucose Test
The FPG is recommended by the ADA as the initial test for screening T2DM, because it
is quick and affordable (American Diabetes Association, 2010). They suggest following
up with another FPG if there are variations in reading. However, the test has the same
issues as the OGTT. Small health behavioral changes may alter readings, and the low
specificity (60%) will miss many positive cases. Reproducibility for this test is 17.6%,
which is much lower than for OGTT (Agency for Healthcare Research and Quality,
2005).
The process for administering the Fasting Plasma Glucose (FPG) test include an 8-hour
fast and a blood sample. A test below 100 mg/dL is considered normal. A test between
100-125mg/dL is considered to indicate higher risk for T2DM, but the threshold for the
disease is greater than 126 mg/dL. People in between are said to have Impaired Fasting
Glucose or IFG.
Small health behavioral changes may alter readings, and the low specificity (60%) will
miss many positive cases (Cosson, 2010). Additionally, the threshold for pre-diabetes
(100 mg/dL) is criticized for being too low of a cut point to justify a diagnosis (Schulze,
2009).
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Hemoglobin A1c
Recently, WHO and ADA changed their diagnostic criteria and screening methods to
include the use of glycated hemoglobin as a more stable detection method. HbA1c, uses
cation exchange chromatography, which is able to detect ions on hemoglobin that are
found in many diabetic patients. Unlike FPG and OGTT, there is no need to fast, and a
small amount of blood is needed to be sampled. (Herman, 2010).
HbA1c is becoming the more widely accepted, in Japan, Australia, and the United
Kingdom because the test is more stable in the preanalytic stage (Nakagami, 2007).
Results of the HbA1c test show average concentrations spanning weeks at a time. Unlike
glucose tests, short-term lifestyle modifications will not alter the results because patients
are not required to fast. Also, the results are not altered by biological variation (Sacks,
2011). These factors affect glucose tests, lower glucose concentration, and can
miscategorize patients.
The HbA1c test measures the percent of glucose in the blood, over the past three months
(Colagiuri, 2011). Patients with values greater than 6.4 % are considered diabetic, less
than 6.4% but greater than 5.5% are pre-diabetic (Nakagami, 2007). Herman also notes
that FGT and OGTT test underestimate glucose levels in those that have pre-existing
blood disorders such as anemia, which can be related to ethnicity (2010). HbA1c is being
accepted in practice in the U.S. to moniter glycemic levels in diabetic patients, and
measures the quality of diabetic care a patient receives (Centers for Disease Control and
Prevention, 2011). Currently, it is not agreed upon whether HbA1c should be used to
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diagnose diabetes (Colagiuri, 2011), yet patient care providers are combining methods
of detection for accuracy (2011).
For example, either the FPG or OGTT will be administered to screen for hyperglycemia,
and can then be followed up with HbA1c as a confirmatory test. This is more of a “stepwise method” of screening for pre-diabetes and T2DM (Nakagami, 2007). There are a
few problems with this method. It was noted by Herman and Fajans that the Intenational
Expert Committee on T2DM recommended against combining methods because of
discordant results (2010). An intial FPG test may show that a person has normal values,
and the HbA1c may show that the patient is diabetic. Misclassification can have mental,
physical and emotional harms to the patient, which must be weighed in choosing to set
HbA1c as a standard method (U.S. Preventive Services Task Force, 2008; American
Diabetes Association, 2010).
Though the HbA1c has promises to help identify high-risk individuals for T2DM, there
have been discprepencies in certain populations. Some populations are predisposed to
hemoglobinopathies such as malaria and sickle-cell anemia, which causes hig red blood
cell turnover experienced in African Americans. Women tend to have lower values
because of conditions of anemia during menstruation, and are at risk for gestational
diabetes while pregnant (Herman W. H., 2007).
2.8-Summary
Ongoing research related to type 2 diabetes mellitus translates into focused programming
and effective interventions around the nation. Unfortunately, the rise and risk of T2DM is ever
increasing with growth of the aging population and high prevalence of obesity and heart disease.
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These conditions are co-morbid with T2DM, and place a large burden on the U.S. healthcare
system. Prevention through screening is essential for reducing the burden of T2DM for all
affected by this chronic condition. It is also important to assess how effective the screening
blood plasma glucose tests are for detecting not only diseased cases, but also those with prediabetes, who are potential cases. This study will assess the effectiveness of the current methods
available. Analysis of the screening methods for pre-diabetes and type 2 diabetes mellitus will
help to determine the effectiveness of detecting the disease in high-risk populations.
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III. METHODS
This study is based on the cross-sectional analysis of the 2005-2006 and 2007-2008
National Health and Nutrition Examination Survey (NHANES), developed by the National
Center for Health Statistics (NCHS). The study highlights risk factors found in the literature such
as age, gender, body mass index (BMI), height, weight, insulin resistance, and others. Data about
glycemic levels were available from the examinations and laboratories files, which displayed
glycemic measures using the FPG, OGTT and HbA1c method.
3.1- National Health and Nutrition and Examination Survey (NHANES)

Since the 1960s, the National Health and Nutrition Examination has set the standards for
healthcare practice. The results of the various surveys set policy and guidelines for health
interventions in U.S. populations, such as the growth charts used by pediatricians in clinical
practice, interventions in obesity, and elimination of lead from gasoline in the 1970‟s. NHANES
data has helped researchers establish trends not only obesity, but also asthma prevalence, and
trends in undiagnosed diabetes. (CDC/National Center for Health Statistics, 2011). The 20072008 version of the survey is the most recent data available for public use. The addition of the
2005-2006 survey adds more power to the study, and provides more reliable estimations of
prevalence and measures of association (CDC/National Center for Health Statistics, 2011).
The surveys and examinations give a cross-section of the status of health for the United
States. Captured in the NHANES questionnaires are prevalence data for the following diseases:
anemia, cardiovascular disease, diabetes, environmental exposures, eye diseases, hearing loss,
infectious diseases, kidney disease, nutrition, obesity, oral health, osteoporosis, physical fitness
and functioning, reproductive history and sexual behavior, respiratory disease, STDs, and vision
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3.2- Data Collection and Measures
NHANES conducts in-home surveys and examinations administered in mobile
examination centers (MECs) to over 5,000 participants, in over 15 counties across the nation
each year. To ensure privacy, respondents use touch screen computers for the computer assisted
self-interview (CASI) or audio computer assisted self-interview (ACASI). Results are sent to
NCHS within 24 hrs. Trained clinicians performed the examinations, and lab and exam results
are stored in a electronic database. This eliminated the need for paper records, and provided
another layer of security for participant health information (CDC/National Center for Health
Statistics, 2011).
The populations surveyed for the analysis included10, 149 participants for 2007-2008 and
10,348 for the 2005-2006 periods. Certain populations such as Blacks, Hispanics, and those over
60 years were oversampled to make the sample represent the national population. NHANES also
aimed to gain more biological information from its aging populations, and researchers
purposefully examined and tested more specimens from the group of those 60 years and older
(CDC/National Center for Health Statistics, 2011).
The demographics files for 2005-2006 and 2007-2008 were combined to obtain
information about each respondent‟s age, gender, education, income, and race/ethnicity. Data
concerning body measures such as height, weight, BMI, systolic blood pressure, and diastolic
blood pressure, were taken from examination files. The laboratory files included the results of
blood tests for cholesterol, triglycerides, and blood plasma glucose.
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Non-Clinical Variables
The study measures obtained from the demographics file needed to be recoded to accommodate
the 10,566 respondents. The following are descriptions of how the variables were recoded:
Age (years): Originally termed, “Age at screening adjudicated-recode”, ranged from 0150 years. The new variable only includes ages 20-80 years of age, and were grouped
{1=20-39}, {2=40-59}, {3=60-80} for descriptive purposes.
Ethnic (independent variable): The original variable termed, “Race/Ethnicity-recode”,
represented five categories where {1=Mexican American}, {2=Other Hispanic},
{3=Non-Hispanic White}, {4=Non-Hispanic Black}, {5=Multi-racial/Other}. The new
variable combined smaller populations to create a larger sample where {1=Non-Hispanic
White}, {2=Non-Hispanic Black}, {3=Mexican American}, {4=Multi-racial/Other}.
Educational Attainment: This variable is created from the “Educational Level-20+”
variables with seven categories where {1=less than 9th grade}, {2=9th-11th grade}, {3=HS
grad/GED or equivalent}, {4=Some college or AA}, {5=College grad or above},
{7=refused}, {9=don‟t know}. The new variable combined these categories by level of
attainment where 5 was coded as {1=High Educational Attainment}, 3 and 4 were coded
as {2=Moderate Educational Attainment}, and 1 and 2 were {3=Low Educational
Attainment}.
Income: This variable is recoded from the “Annual Household Income” measure where,
{1=$0-$4,999}, {2=$5,000-$9,999}, {3=$10,000-$14,999}, {4=$15,000-$19,999},
{5=$20,000-$24,999}, {6=$25,000-$34,999}, {7=$35,000-$44,999}, {8=$45,000$54,999}, {9=$55,000-$64,999}, {10=$65,000-$74,999}, {12=over $20,000},
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{13=under $20,000}, {14=$75,000-$99,999}, {77=refused}, {99=don‟t know}. The new
variable combined these categories, and used the poverty level for 2005 and 2008 to
determined low-income status ($21,200). Categories 1-5 and 13 were coded {3=LowIncome}, 6-9 and 12 were coded {2=Middle-Income}, and 14 and 15 were coded
{1=High-Income}.
Weight (kg): This variable is recoded from the “Weight” variable ranging from 32.4 kg
(about 70 lbs) to 371.0 kg (about 600 lbs). These cases were compressed into four
different categories where {1=32.4 kg-83.6 kg}, {2=83.7 kg-164 kg}, {3=165 kg-200
kg}, and {201 kg-371 kg}.
Height (cm): This variable is recoded from the “Height” variable ranging from 137.3 cm
(about 4-ft.4-in.) to 204.1 cm (about 6-ft.7-in). These cases were compressed into four
different categories where {1=137.3 cm-158.5 cm}, {2=158.6 cm-169.9 cm}, {3=170
cm-185 cm}, and {4=186 cm-204.1 cm}.
BMI (kg/m2): This variable is recoded from the “Body Mass Index (kg/m**2)” variable
ranging from 13.36 kg/m2 to 130.21 kg/m2. The values are organized according to the
CDCs categorizations of body mass indices, where values up to 18.4 kg/m2 were coded
{1=Underweight}, values 18.5 kg/m2-24.9 kg/m2were coded {2=Healthy Weight},
values 25.0 kg/m2-29.9 kg/m2 were coded {3=Overweight}, and values 30 and above
were coded {4=Obese}.
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Clinical Variables
The combined examination, laboratory surveys and diabetes, blood pressure, HDL cholesterol,
LDL cholesterol, and triglyceride questionnaires provide health behaviors regarding medications
used, and the presence of risk factors that are co-morbid with T2DM. The following are
descriptions of the clinical variables:
Hypertension: This variable is computed from the “Systolic: Blood pres (2nd reading)
mm Hg”, “Diastolic: Blood pres (2nd reading) mm Hg”, “Systolic: Blood pres (3rd
reading) mm Hg”, and” Diastolic: Blood pres (3rd reading) mm Hg” to create the mean
systolic (MSBP) and mean diastolic blood pressure (MDBP). MSBP, including values
greater than or equal to 140 mmHg, MDBP values greater than or equal to 90 mmHg are
defined as hypertensive. In addition to the biological measures, answering “yes” to the
questions, “Ever told you had high blood pressure?” and “Taking prescription for
hypertension?” identified cases that are hypertensive.
Total Cholesterol (mg/dL): “Total Cholesterol (mg/dL)” is recoded into three categories.
Values up to 199 mg/dL were coded {1=Poor}, values including 200 mg/dL up to 239
mg/dL were coded {2=Moderate}, and values of 240 mg/dL and above were coded
{3=High}.
HDL (mg/dL): “Direct HDL-Cholesterol (mg/dL)” is recoded into three categories,
which differ for men and women. Values up to 40 mg/dL for men were coded {1=Poor},
values 41 mg/dL up to 59 mg/dL were coded {2=Moderate}, and values of 60 mg/dL and
above were coded, {3=High (best)}. For women, values less than 50 mg/dL were coded
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{1=Poor}, values 51 mg/dL up to 59 mg/dL were coded {2=Moderate}, and 60 mg/dL
were coded {3=High (Best)}.
LDL (mg/dL): “LDL-cholesterol (mg/dL)” is recoded into three categories with values up
to 99 mg/dL coded as {1=Good}, values of 100 mg/dL to 159 mg/dL coded as
{2=Moderate}, and values of 160 mg/dL above coded as {3=High}.
Triglycerides (mg/dL): “Triglyceride (mg/dL)” is recoded into three categories with
values up to 149 mg/dL coded as {1=Good}, values of 150 mg/dL up to 199 mg/dL
coded as {2=Moderate}, and values 200 mg/dL and above coded as {3=High}.
Dyslipidemia: This variable is computed from the newly created variables of HDL, LDL,
Triglycerides, and answering yes to the questions “Doctor told you - high cholesterol
level?” and “Now taking prescribed medicine (for high cholesterol)?”.
Impaired Glucose Tolerance (mg/dL): This variable is computed by selecting cases if the
value for the variable “OGTT (200 mg/dL)” is between 140 mg/dL and 199 mg/dL. This
establishes the prevalence of those that are pre-diabetic by using the oral glucose
tolerance test as the screening method.
Impaired Fasting Glucose (mg/dL): This variable is computed by selecting cases if the
value for the variable “FPG (126 md/dL)” is between 100 mg/dL and 125 mg/dL. This
establishes the prevalence of those that are pre-diabetic by using the fasting plasma
glucose test as the screening method.
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Higher-risk for T2DM (%): This variable is computed by selecting cases if the value for
the variable “HbA1c (6.5%)” is between 5.5-6.4%. This establishes the prevalence for
those that are higher-risk for T2DM, or pre-diabetic.
OGTT: This variable is computed by selecting cases if the value for the variable “OGTT
(200 mg/dL)” is greater than or equal to 200 mg/dL. This establishes the prevalence of
those that are diabetic by using the oral glucose tolerance test as a screening method.
FPG: This variable is computed by selecting cases if the value for the variable “FPG (126
md/dL)” is greater than or equal to 126 mg/dL. This establishes the prevalence for those
that are diabetic by using the fasting plasma glucose screening method.
HbA1c: This variable is computed by selecting cases if the value for the variable “HbA1c
(6.5%)” is greater than or equal to 6.5%. This establishes prevalence of those that are
diabetic by using the HbA1c as a diabetic maintenance tool.
3.3-Statistical Methods
The Statistical Package for the Social Sciences (SPSS 19.0) PASW is the software used
to run tests of agreement and concordance of screening methods for pre-diabetes and T2DM. The
analysis is stratified by race/ethnicity and gender to observe differences in distributions of prediabetes and T2DM status by screening method. Agreements of the linear relationships of each
screening method are assessed using the partial correlations function. Significance for each
analysis is set at a p-value of .05, and p-values <.01 for highly significant findings.
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The cross tabulations function will reveal any significant differences in screening detection
of pre-diabetes and T2DM by race/ethnicity and gender, and significance of co-morbidities in the
study sample. The statistical difference is provided by Pearson‟s chi-square. Differences in
detection for males and females will be determined by the one-way analysis of variance
(ANOVA). Concordance of the FPG and HbA1c against the OGTT (gold standard), will
determine the following:
Sensitivity- This is the ability for the screening test to identify patients as pre-diabetic or
diabetic.
Specificity- This is the ability for the screening test to identify patients as not pre-diabetic
or diabetic.
Positive Predictive Value- This is the number of those that test positive for pre-diabetes
and diabetes that truly have the disease.
Negative Predictive Value- This is the number of those that test negative for pre-diabetes
and diabetes and truly do not have the disease.
Overall Agreement-This value reflects the measure of equal outcomes of a screening
method to OGTT (gold standard).
Cohen‟s Kappa-This value expresses the level of agreement of the screening methods
corrected beyond chance, where K≤.4 equals weak agreement, K≥.5 equals moderate
agreement, and K≥.6 equals strong agreement (Kleinbaum, 2008).
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IV. RESULTS
4.1-Descriptive Statistics
Table 1 and Table 2 shows the frequency of clinical and non-clinical variables for men
and women based on race and ethnicity. The mean age range for all respondents was 43-52 years,
with Mexican Americans (MA) comprising more of the younger ages, and non-Hispanic whites
(NHW) being older. Men and women of all race and ethnicities have significant differences in
mean age, weight, BMI, educational attainment and income at a p-value <.01. Dyslipidemia was
highest in NHW men (55%), while hypertension was highest for NHB men (47%). The
measurement of blood glucose levels differed for all men, with MA men having the highest
values for OGTT (127 mg/dL) and FPG (111 mg/dL). Non-Hispanic black men had the highest
reading for the HbA1c test at 5.93%.
For women, mean BMI (kg/m2) was highest in non-Hispanic black females (31.2 kg/m2),
which was significantly different from all other groups. Hypertension was also highest in nonHispanic black females (49%), and dyslipidemia was most prevalent in non-Hispanic white
females (47%). The mean blood glucose was highest for MA women using the OGTT (134
mg/dL) and FPG (112 mg/dL), but highest for NHB women for the HbA1c (5.84%).
4.2-Gylcemic Indices and Disease Prevalence
The data shows that there are significant differences in mean glycemic levels for males
and females based on race and ethnicity. Table 1 and Table 2 also show that each screening
method captured different proportions of disease. The OGTT captured the least amount of men
classified as pre-diabetic (13-20%), where the FPG and HbA1c methods captured over 37% of
cases of men that are pre-diabetic. However, the OGTT captured more diabetic cases than the
other two methods (25-38%) compared to the FPG and HbA1c that captured less than 15% of
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T2DM. For women, the OGTT captured the least amount of pre-diabetes for NHW, NHB and
Multiracial/other groups (12-23%). This finding was not true for MA women, where all three
methods detected comparable pre-diabetes with OGTT (31%), FPG (34%), and HbA1c (33%).
Type 2 diabetes mellitus was best detected by OGTT for all race/ethnicities in women (39-42%),
with NHB having the highest proportion of diabetics using this method. The other two methods
detected less than 15% of diabetic cases.
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Table 1. Distribution of characteristics of Males age 20 to 80 in the (2005-2008) National
Health and Nutrition Examination Survey
NHW

NHB

MA

Multiracial/Other

X2

p-value

Male Sample Profile
n=5,138
2475
1119
966
578
------Age (years)
52
48
44
47
101.7 .000**
Educational Attainment
2
2
3
2
598 .000**
Income
2
2
2
2
51
.000**
Weight (kg)
89.4
90.3
82.1
81.2
125 .000**
Height (cm)
176.5
176.6
169.2
170.3
713.8 .000**
BMI (kg/m2)
28.6
28.9
28.5
27.9
48.2
.018*
SBP (mmHg)
124.4
127.4
123.1
123.3
355
0.559
DBP (mmHg)
71
73.4
70.4
72.2
338 .002**
Total Cholesterol (mg/dL)
192
189.7
201.7
200.9
42.4 .000**
HDL (mg/dL)
47.1
52.4
45.9
46.3
101.8 .000**
LDL (mg/dL)
113.2
113.1
119.3
122.8
25.6 .000**
Triglycerides (mg/dL)
146.6
130.4
153.6
148
14.1
0.055
Co-morbidities Profile
Hypertension (%)§
41%
47%
27%
33%
109.8 .000**
Dyslipidemia (%)¥
55%
44%
48%
50%
36.3
.000*
Mean Glycemic Indices
2-hr Oral Glucose (mg/dL)
122.7
112.7
127.5
125.5
749
0.498
Fasting Glucose (mg/dL)
106.9
108.7
111.1
108.3
501
0.213
Glycohemoglobin (%)
5.58
5.93
5.78
5.68
456 .000**
Pre-diabetes Profile by Method
IGT: OGTT+
20%
13%
17%
19%
7.67
0.053
IFG: FPG+
41%
37%
43%
50%
8.68
.034*
High-risk: HbA1c+
38%
51%
38%
45%
19.2 .000**
T2DM Profile by Method
Diabetic: OGTT+
37%
25%
35%
38%
12.4 .006**
Diabetic: FPG+
11%
14%
12%
7%
8
.045*
Diabetic: HbA1c+
8.7%
15%
12%
9%
71.5 .000**
p<.05*, p<.01**Data are means, unless indicated, §Hypertension if systolic/diastolic BP ≥140/90
mmHg, diagnosed with hypertension, taking medication. ≦Dyslipidemia if HDL≤35, LDL≥160
mg/dL, Total Cholesterol ≥200 mg/dL, Triglycerides ≥200 mg/dL, and taking medications for
any of these conditions. +Percent of prevalence. P values were from X2 test of means.
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Table 2- Distribution of characteristics of Females age 20 to 80 in the (2005-2008) National
Health and Nutrition Examination Survey
NHW

NHB

MA

Multiracial/Other

X2

p-value

Female Sample Profile
n=5,428
2,495 1,199 1,050
684
------Age (years)
50
47
43
46
95
.000**
Educational Attainment
2
2
2
2
560
.000**
Income
2
2
2
2
53.7
.000**
Weight (kg)
74.9
83.9
73
70.5
169.8 .000**
Height (cm)
162.7 162.7 157
157.6
625
.000**
BMI (kg/m2)
28.3
31.5
29.7
28.3
165.5 .000**
SBP (mmHg)
121.4 125.1 118.4
117.7
474
.001**
DBP (mmHg)
68.3
69.5
66.2
66.7
369
.001**
Total Cholesterol (mg/dL)
205.4 195.8 199.6
199.6
22.9
.000**
HDL (mg/dL)
59.1
61.5
54.7
56
77
.000**
LDL (mg/dL)
117.3 112.4 114.3
113
4.8
.061
Triglycerides (mg/dL)
135.8 112.3 139.1
125.8
37.2
.000**
Co-morbidities Profile
Hypertension (%)§
38%
49% 28%
33%
122.6 .000**
Dyslipidemia (%)¥
47%
39% 38%
41%
30.2
.000**
Mean Glycemic Indices
2-hr Oral Glucose (mg/dL)
121.7 117.1 134
121
681
.469
Fasting Glucose (mg/dL)
104
108.3 112
102.4
510
.796
Glycohemoglobin (%)
5.47
5.84
5.67
5.66
270
.000***
Pre-diabetes Profile by Method
IGT: OGTT+
19%
12% 31%
23%
15.7 .001**
IFG: FPG+
32%
35% 34%
35%
2.2 0.532
High-risk: HbA1c+
35%
42% 33%
38%
19.2 .000**
T2DM Profile by Method
Diabetic: OGTT+
38%
29% 42%
39%
12.4 .006**
Diabetic: FPG+
7.3% 13% 14%
7%
8
.045*
Diabetic: HbA1c+
9%
15% 11%
11%
71.5 .000**
p<.05*, p<.01**Data are means, unless indicated, §Hypertension if systolic/diastolic BP ≥140/90
mmHg, diagnosed with hypertension, taking medication. ≦Dyslipidemia if HDL≤35, LDL≥160
mg/dL, Total Cholesterol ≥200 mg/dL, Triglycerides ≥200 mg/dL, and taking medications for
any of these conditions. + Percent of prevalence. P values were from X2 test of means.
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4.3- Partial Correlations and Concordance of Screening Methods by Race/Ethnicity and Gender
Partial correlations (r) are shown in Table 3 and Table 4. This analysis assesses the
strength of the linear relationship of the screening method versus the health status, while
controlling for age (yr) and BMI (kg/m2). The correlation is a measure of the degree and
direction of the relationship of health status and screening method, where pre-diabetes is IFG,
IGT, Higher-Risk, and T2DM status is OGTT, FPG and HbA1c. The results show that even after
controlling for age and BMI, there are significant correlations for detecting pre-diabetes and
T2DM, based on race/ethnicity and gender.
Non-Hispanic white men and women show a positive, yet weak correlation of prediabetes status while using the FPG method for screening (r=.12-.17). Correlation becomes
negative for the FPG test and HbA1c for both NHW men and women, as the blood glucose
thresholds increase. In NHB men, the correlations are all negative when comparing the FPG test
with pre-diabetes and diabetes status (r≤ -.22). The same is not true for NHB women where the
correlation is positive for pre-diabetes and diabetes status (r= -.27) Mexican American men and
women showed positive correlations for most screening methods, as did Multiracial/Other men
and women. For all men, pre-diabetes diagnosis showed significant correlation for diagnosis of
diabetes in relation to the FPG test (r=.333-.440). The correlation of OGTT with T2DM
diagnosis showed the most positive correlation for all men and women with the FPG and HbA1c
tests (r=.554-.687).
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Table 3-Partial Correlations of FPG, OGTT, and HBA1c by Race/Ethnicity: Males age 20- 80 years
in the (2005-2008) National Health and Nutrition Examination Survey
NHW
1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1
1
0.130**
0.140**

2

3

1
0.146**

1

0.013**
-0.288**
-0.072

0.644**
-0.053
-0.182**

0.134**
0.010
-0.182**

4

5

6

1
0.148**
0.155**

1
0.333**

1

4

5

6

NHB
1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1
1
-0.058

2

3

0.291**

0.154**

1

-0.103
-0.220**
-0.174**

0.687**
0.702
-0.550

0.014
-0.169*
-0.283**

1
0.182*
0.243**

1
0.362**

1

4

5

6

1
.178**
.248**

1
0.435**

1

4

5

6

1

1
1
0.142**
0.202**

2

MA
3

1
0.024

1

0.124
-0.302**
-0.121

0.596**
-0.053
-0.053

0.01
0.041
-0.226**

1
1
0.042

2

Multiracial
3

1. IFG
1
2. IGT
3. High-0.047
1
0.209*
Risk
0.554**
-0.067
-0.016
1
4. OGTT
0.012
-0.103
-0.253
0.031
1
5. FPG
-0.072
-0.123
-0.111
0.132
0.440**
1
6. HbA1c
p<.05*, p<.01**IFG, IGT and High-Risk are diagnostic methods for pre-diabetes status, and
OGTT, FPG and HbA1c for diabetes diagnosis. The strength of the partial correlation (r) is
measured from -1 to 1.
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Table 4- Partial Correlations of FPG, OGTT, and HBA1c by Race/Ethnicity: Females age
20- 80 years in the (2005-2008) National Health and Nutrition Examination

1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1. IFG
2. IGT
3. HighRisk
4. OGTT
5. FPG
6. HbA1c

1

2

NHW
3

1
0.125**
0.171**

1
0.076

1

0.091
-0.216**
-0.090

0.638**
-0.048
-0.703

1
1
0.082
0.119

2

0.092*
-0.076
-0.208**
NHB
3

1
0.218**

1

0.089
-0.270**
-0.104

0.569**
-0.044
-0.157*

1
1
0.176*
0.214**

4

5

6

1
0.118**
0.129**

1
0.303**

1

4

5

6

0.151*
-0.098
-0.355

1
0.189**
0.069

1
0.478**

1

2

MA
3

4

5

6

1
0.184*

1

0.187*
-0.249**
-0.163*

0.690**
-0.129
-0.116

0.171*
-0.128
-0.210**

1
-0.046
0.107

1
0.231**

1

1
1
0.161
0.15

2

Multiracial
3

4

5

6

1. IFG
1
2. IGT
3. High0.156
1
Risk
0.098
0.596**
0.237*
1
4. OGTT
-0.146
-0.089
-0.020
0.074
1
5. FPG
-0.085
-0.065
-0.117
0.117
0.503**
1
6. HbA1c
p<.05*, p<.01**IFG, IGT and High-Risk are diagnostic methods for pre-diabetes status,
and OGTT, FPG and HbA1c for diabetes diagnosis. The strength of the partial correlation
(r) is measured from -1 to 1.
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The measures of concordance are displayed in Table 5, and show the results for men and
women by race/ethnicity. Sensitivity of the screening methods are low for all racial and ethnic
groups, yet NHB and Multiracial/other groups are being detected as high-risk for pre-diabetes
about 64% of the time using the HbA1c method versus the OGTT method. The kappa is weak
(k=.135), but significant for this finding.
The prevalence for pre-diabetes was highest in NHBs and MAs, and the overall
agreements for the screenings were highest in these groups. Detecting pre-diabetes in NHB was
most effective using the OGTT test (86%), while the FPG and HbA1c tests were comparable in
agreement for this group (75%). Positive predictive value was 72% for the HbA1c method for
NHBs. Though sensitivity for detecting pre-diabetes in NHWs (55%) was highest using the
HbA1c method for pre-diabetes, overall agreement was higher using OGTT to diagnose prediabetes. Diabetes diagnosis using the FPG method (71%) agreed more than using HbA1c (65%)
for NHWs. Pre-diabetes was best detected using OGTT (82%), with HbA1c and FPG close in
precision (61%) for the MA group. The results for the Multiracial/other group differ where the
overall agreement for FPG (76%) is higher than HbA1c (67%).
The fasting plasma glucose detects between 44%-66% of those with T2DM, while the
HbA1c method correctly detects (72%-100%) of cases for all racial and ethnic groups. Though
the results are different, values of kappa are closer to zero than one. This could indicate that the
concordance or discordance of the screening is most likely due to chance.
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Table 5-Concordance of FPG and HbA1c against OGTT for Males and Females age 20-80
years in the (2005-2008) National Health and Nutrition Examination Survey
NHW
Sen.
52%

Spec.
67%

PPV
45%

NPV
73%

K

OA

.183**

62%

IGT
High-Risk
FPG

54%
55%

100%
70%

100%
51%

79%
73%

.602**
.241**

83.3%
64%

13%

96%

64%

68%

0.113

71.6%

HbA1c

6%

100%

95%

65%

0.067

65.4%

IFG

NHB

IFG

Sen.
42%

Spec.
67%

PPV
32%

NPV
75%

K
0.08

OA
60%

IGT

46%

100%

100%

75%

.568**

86%

High-Risk

66%

52%

33%

80

.135**

56%

FPG

18%

96%

66%

75%

.185**

75.10%

HbA1c

13%

98%

72%

75%

0.174

75.30%

MA
Sen.
53%

Spec.
64%

PPV
46%

NPV
70%

K

OA

IFG

.164**

60%

IGT

54%

100%

100%

78%

.588**

82.2%

High-Risk

50%

67%

49%

68%

.120**

61%

FPG

15%

95%

65%

66%

0.12

45.3

HbA1c

9.7%

100%

100%

64%

.118**

100

Sen.

Spec.

Multiracial
PPV

NPV

K

OA

IFG

52%

59%

47%

64%

0.116

57%

IGT

59%

100%

100%

78%

0.603**

82.7%

High-Risk

64%

65%

54%

74%

.285**

65%

FPG

5%

96%

44%

59%

0.007

76.4%

HbA1c

5%

100%

100%

62%

0.062

67%

p<.05*, p<.01**, Sensitivity, Specificity, Positive Predictive Value, Negative Predictive
Value, Cohen‟s Kappa (K), Overall Agreement are all measured. K ranges from 0 to 1 to
show measure of agreement.
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4.4-Gender as a Risk Factor
This last analysis observes differences in glycemic indices during time of examination to
see if these measures may have an impact on whether or not a respondent is pre-diabetic or
diabetic. The one-way ANOVA displays diabetes status of pre-diabetic or diabetic in relation to
gender. The means of the glycemic indices are compared for significance (see Table 6). The
results show that there is a significant difference in glycohemoglobin (%), which is measured by
the HbA1c method (p=.000), with the mean value for men being 5.7% and 5.6% for women. Prediabetes status was also significantly different for men and women with men more likely to have
impaired fasting glucose (42%) compared to women (33%). Being tested using the HbA1c
method and testing high-risk was significantly different in males (41%) from females (37%).
Differences of the means for the FPG and OGTT measures were not significantly different for
males and females.
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Table 6- One-Way ANOVA of Glycemic Measures for Males and Females age 20 to 80
years in the (2005-2008) National Health and Nutrition Examination Survey

Std.
N
Mean Deviation
1689 122.13
56.120

95%
Confidence
Interval for
Mean
Std.
Lower Upper
Error Bound Bound Minimum Maximum
1.366 119.45 124.81
33
490

F
.180

Sig.
.671

2.612

.106

Two Hour
Glucose †
(mg/dL)

male

female 1595 122.92
Total
3284 122.51

49.945
53.204

1.251 120.47 125.37
.928 120.69 124.33

23
23

421
490

Fasting †
Glucose (mg/dL)

male
1870 108.27
female 1976 106.38
Total
3846 107.30

33.785
38.334
36.201

.781 106.74 109.80
.862 104.69 108.07
.584 106.16 108.45

45
38
38

440
584
584

1.09271
1.00662
1.05012
.47652

.01606 5.6741 5.7370
.01433 5.5849 5.6411
.01074 5.6367 5.6788
.01159 .3254 .3709

3.70
2.00
2.00
.00

15.20 18.587 .000**
15.60
15.60
1.00
.349
.555

.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00

1.00
1.00
1.00
.069
.792
1.00
1.00
1.00 3.284
.070
1.00
1.00
1.00 34.172 .000**
1.00
1.00
1.00
.491
.484
1.00
1.00
1.00 20.731 .000**
1.00
1.00

Glycohemoglobin† male
(%)
female
Total
OGTT ‡
male
(mg/dL)
female
Total
FPG ‡
male
(mg/dL)
female
Total
HbA1c ‡
male
(%)
female
Total
Impaired Fasting
male
Glucoseª
female
Total
Impaired Glucose
male
Toleranceª
female
Total
Higher Risk for
male
T2DMª
female
Total

4627 5.7056
4937 5.6130
9564 5.6578
1689 .3481
1595
3284
1870
1976
3846
4627
4937
9564
1870
1976
3846
1689
1595
3284
4627
4937
9564

.3580
.3529
.1166
.1139
.1152
.1076
.0964
.1018
.4182
.3274
.3716
.1835
.1931
.1882
.4132
.3678
.3898

.47956
.47795
.32100
.31773
.31929
.30994
.29519
.30245
.49339
.46939
.48328
.38722
.39486
.39092
.49247
.48226
.48773

.01201
.00834
.00742
.00715
.00515
.00456
.00420
.00309
.01141
.01056
.00779
.00942
.00989
.00682
.00724
.00686
.00499

.3344
.3366
.1020
.0998
.1051
.0987
.0882
.0958
.3958
.3067
.3563
.1651
.1737
.1748
.3990
.3544
.3800

.3815
.3693
.1311
.1279
.1253
.1166
.1047
.1079
.4406
.3481
.3868
.2020
.2125
.2016
.4274
.3813
.3996

†The measurements indicate blood glucose reading at time of examination. ‡ This reading
indicates T2DM status by method of screening. ª These values indicate pre-diabetes status by
screening method. Significance was derived from the ANOVA and F-statistic test of the ratio of
variance within and between groups.
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4.5-Research Questions
Question #1-- Is there an agreement between the fasting plasma glucose test and HbA1c and
against the oral glucose tolerance test for detecting type 2 diabetes mellitus based on
race/ethnicity and gender?
The partial correlations and concordance measures suggest that there is weak to moderate
agreement between the fasting plasma glucose test and HbA1c, but this is dependent on
race and ethnicity and gender. Non-hispanic white (r=.33), NHB (r=.36), MA (r=.43),
and Multiracial/Other men (r=.44) had positive, and moderate correlations between the
FPG and HbA1c measures for detecting T2DM. For NHW (r=.30), NHB (r=.48), MA
(r=.23), and Multiracial/Other women (r=.50), the correlations were moderately
associated with each other for the FPG and HbA1c methods for detecting T2DM. The
partial correlations differed for men and women, with the partial correlation higher in
women that are NHB and Multiracial/other. These correlations show that the higher the
value of the FPG test, the higher the value for the HbA1c test.
The concordance measures of sensitivity, specifity, positive predictive value, negative
predictive value, kappa, and overall agreement were measured for FPG and HbA1c
against OGTT. In terms of agreement, the OA for NHB using the FPG against OGTT
was 75% (k=.185). Mexican Americans also had perfect OA (100%) for the HbA1c test
(k=.118). Both values have low kappa measures, which indicate poor agreement, or that
agreement is the result of chance alone. These results suggest that though the FPG and
HbA1c tests are moderately correlated with each other, there are significant differences in
the diagnostic outcomes of T2DM for the different races and ethnicities.
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Question #2- Is there an agreement between the fasting plasma glucose test and HbA1c and
against the oral glucose tolerance test for detecting pre-diabetes mellitus based on race/ethnicity
and gender?
Partial correlations for detecting pre-diabetes by screening method were significant for
some groups of men and women but not others. For example, the FPG correlated with
OGTT (r=.13) and HbA1c (r=.14) for NHW men and for MA men (r=.14, .20),
respectively. The FPG test was not significantly correlated with OGTT for NHB or
Multiracial/other men. The HbA1c method correlated significantly with OGTT for both
NHW (r=.15) and NHB (r=.15) men.
The partial correlations for women showed poor correlations between FPG and OGTT for
NHWs (r=.13) and MA (r=.17) women. Fasting plasma glucose correlated significantly
with HbA1c for NHW (r=.17) and MA (r=.21) women. There were no significant
correlations for NHB and Multiracial/other women for the FPG test. The HbA1c test
correlated significantly with OGTT for MA (r=.18) and Multiracial/other women (r=.18).
Overall agreement between FPG and OGTT for detecting pre-diabetes for NHW
(OA=62%, k=.18) and for HbA1c (OA=64%, k=.24). Significant findings also occurred
for the FPG in MA (OA=60%, k=.16). The HbA1c showed agreement with the OGTT test
for NHB (OA=56%, k=.14), MA (OA=61%, k=.12) and for Multiracial/others (OA=65%,
k=.28).
These results suggest that the HbA1c method may be appropriate for use in detecting
potential cases of T2DM. Minority groups had significant overall agreement for the
HbA1c test over the FPG test. The partial correlations for detecting pre-diabetes were
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much lower, showing little no linear relationship between screening method and prediabetes status as the outcome.
Question #3-Are the screening methods effective in detecting pre-diabetes and type 2 diabetes
mellitus for all race/ethnicities?
The distribution of disease status varied in racial and ethnic populations, and for men and
women. For men and women, the fasting plasma glucose test dected less than 14% of
cases compared to the oral glucose tolerance test which detected over 25%. The group of
Multiracial/other men had the highest prevalence of T2DM (38%) compare the NHB men
(25%). The hemoglobin A1c test found comparable cases of T2DM as the FPG with 8%15% of cases being within the category.
The oral glucose tolerance test found 42% of Mexican American women to have T2DM,
where the FPG only detected 14% of the disease in the same group. All other women
were most likely to be categorized as diabetic by the OGTT method (29%-38%), over the
FPG and HbA1c methods (7%-15%).
Senitivities for detecting pre-diabetes were much higher ranging in 50%-66% for all
racial and ethnic groups using the HbA1c method. The FPG method showed much lower
sensitivities ranging in values of 42%-53% for all groups. The HbA1c yielded more
positive cases for pre-diabetes compared to the FPG.
In addition, sensitivites for detecting T2DM, were low for all groups (≤18%), but the
PPV of HbA1c test versus the OGTT ranged from 75%-100%. The values were much
lower for the FPG test (44%-72%) in all racial and ethnic groups. This indicates that the
HbA1c could be as effective a screening method compared to the widely used FPG test
for all races and ethnicities.
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Question #4- Are the screening methods effective in detecting pre-diabetes and type 2 diabetes
mellitus for both males and females?
Results of the one-way ANOVA showed there are differences in diagnosis of prediabetes between men and women. Men in this sample are more likley to test as prediabetic using the FPG at 42% which is 10% more than women for the category of
impaired fasting glucose. Men were also more likley to be at higher-risk for T2DM using
the HbA1c method at 41% compared to women at 37%. The HbA1c method is capturing
similar proportions of pre-diabetes as the FPG for men and women, though women are
being diagnosed less frequently. However, the HbA1c method detected the higher
proportions of pre-diabetes for non-Hispanic black men (51%) and women (42%), MA
women (33%), and Mutliracial other women (38%) than the FPG.
The OGTT screening method yielded the highest proportion of cases of T2DM, while
both the FPG and HbA1c captured up to 30% fewer cases than OGTT for men and
women. Throughout all analyses, the OGTT screening method showed the strongest
correlations (r≥.6), kappa (≥.5), and OA (≥80%), which is consistent with the literature.
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V. DISCUSSION and CONCLUSION
5.1-Discussion
The purpose of this study was to compare the effectiveness of the fasting plasma glucose
test, oral glucose tolerance test, and HbA1c for detecting pre-diabetes and type 2 diabetes
mellitus in high-risk populations such as racial and ethnic minorities and women. An analysis of
NHANES (2005-2008) data was performed, and showed that there were differences in rates of
detection. There were also significant differences in concordance of the FPG and HbA1c tests
against the OGTT (gold standard). The results show that the OGTT is still most accurate in
detecting T2DM for all race/ethnicities, and for men and women (OA≥80%, k≥.5). The FPG and
HbA1c were poorer at detecting T2DM in the study sample, yet HbA1c detected pre-diabetes at
sensitivities higher than FPG for NHW (55% vs. 52%), NHB (66% vs. 42%), and
Multiracial/other (64% vs. 52%). The values were almost the same for MAs (50% vs. 53%).
Though the positive predictive value for FPG was around 60% for NHW, NHB and MA
groups, the value was only 44% for the Mutliracial/other group for detecting T2DM. This shows
that compared to the oral glucose tolerance test (80%), there are many cases being missed in
high-risk groups. The overall agreement is high for the fasting plasma glucose test in NHW and
NHB, and Multiracial/other groups (75%) compared to the oral glucose tolerance test, yet kappa
(.007-.185) showed low agreement. These findings are likely due to chance. This may explain
why the overall agreement is low for the MA group, and high for the others. Positive predictive
values are also high for the HbA1c (72-100%) in all groups. The measure of agreement for all
racial and ethnic groups had a kappa of ≤.185, which is weak.
The one way-ANOVA was used to assess diabetes status by gender. Men of all
race/ethnicities compared to women of all race/ethnicities showed significantly different means
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for testing as being pre-diabetic using the FPG (42%) and HbA1c (41%) methods. The results
also show that the HbA1c method detected higher proportions of pre-diabetes for non-Hispanic
black men (51%) and women (42%), MA women (33%), and Mutliracial other women (38%)
than the FPG.
Screening methods were assessed for all men and women in each racial and ethnic group.
Partial correlations compared health status (pre-diabetic vs. diabetic) to the screening method
used to detect the condition. The OGTT is the gold standard for screening T2DM, and showed
the strongest linear relationship (r>.6) for all racial and ethnic groups. HbA1c is considered the
next best method (Agency for Healthcare Research and Quality, 2005), but showed weak to
moderate partial correlation with the FPG in the NHB men (r=.362), MA men (r=.435) and
Multiracial men (r=.440). A weak to moderate linear relationship is also seen for NHB women
(r=.478) and for Multiracial/other women (r=.503) while comparing FPG. At times the results
showed major significance, but when analyzed more closely; the kappa and partial correlations
were mostly weak.
This study is important because it was found that the HbA1c test is comparable in
precision, and is correlated with the FPG for racial and ethnic minorities. The specificities for
detecting pre-diabetes using the HbA1c were higher (64-66%) for these groups than by using the
standard, FPG screening method (42-49%). This study also recognizes that there are different
outcomes for screening for pre-diabetes and T2DM. The same outcome has been found for other
studies (American Association of Clinical Endocrinologists Board of Directors and American
College of Endocrinologists Board of Trustees, 2010).
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Overall, this study identifies the possibility of incorporating the HbA1c method for
targeted screening for pre-diabetes in men and women that are NHB, MA, and Multiracial/Other
because the measures of concordance were strong for each group (Specificity, PPV, NPV, OA).
The role of gender assessed during the ANOVA showed men being at an increased risk for
T2DM rather than women.
5.2- Strengths and Limitations
A major strength of this study is the use of a large, nationally diverse sample for analysis
from a robust data source funded by the National Center for Health Statistics. The study also
analyzes the use of HbA1c in U.S. populations while others have taken place overseas (SantosRey, 2010; Saukkonen, 2010; Nakagami, 2007). Some of the limitations include the inability
obtain higher sensitivities to compare the screening test for the effectiveness of screening for
T2DM.
Many of the cases were lost while creating sub-categories for pre-diabetes and T2DM
status because not all cases fit the descriptions for recoded variables. The samples sizes were
already disproportionate during the initial survey, where the size of NHB, MA, and
Multiracial/other groups were less than half of the population for non-Hispanic whites. Any loss
of cases could bias the results to show more than they should. For example, where the sensitivity
showed perfect agreement for the HbA1c test in Multiracial other groups, there were no cases
counted in the calculation. This resulted in a one-to-one ratio, and the value could have been
nothing more than a missing case.
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5.3-Conclusions and Recommendations
The relationship of race/ethnicity and gender were considered while comparing the
effectiveness of screening tests for pre-diabetes and T2DM. The ability for the OGTT, FPG and
HbA1c to screen effectively for minorities has been disputed in the literature (Ariza, 2010; Borai,
2011; Colagiuri, 2011). This study is important because this study provides additional
information for better detection of pre-diabetes and T2DM for racial and ethnic minorities, who
bear a higher burden of T2DM (National Center for Chronic Disease Prevention and Health
Promotion, 2011). Prevention is essential for reversing or delaying pre-diabetes and T2DM, and
HbA1c could be added as a standard method of detection. However, the current concern is that
the HbA1c method will misdiagnose racial and ethnic minorities (Borai, 2011; Carnethon, 2002;
Esakoff, 2005 ; Olson, 2010).
One recommendation is for further research of more survey years from NHANES to help
assess the effectiveness of screenings, which will include more data points. This can validate this
and other studies about screening to better inform clinicians about their options (Bisht, 2011).
More academic research will aid in improving policy for screening. Updated health policy can
include the HbA1c as a standard precursor to the FPG or OGTT during initial screening for prediabetes or T2DM, because it is the most stable testing method (Borai, 2011). While there is
evidence supporting focused screening for those that have hypertension and dyslipidemia (U.S.
Preventive Services Task Force, 2008, American Diabetes Association, 2010), the USPSTF
recommends more studies to be done to support focused screening for other risk factors (2008).
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